A medicine’s potential for approval should already be recognisable as early as the transition phase between research and development. Meticulous and thorough scrutiny should reveal all the risks,
as well as the opportunities. Which prescription-drug candidates have the best prognosis for approval? Which product-information is important? Under which conditions do the specifications adhere
best to the terms of regulatory compliance?
The early regulatory-compliant selection of promising candidates lowers
the investment costs.